Spero Therapeutics Inc (SPRO) USD0.001

Sell:$0.73Buy:$0.73$0.00 (0.29%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$0.73
Buy:$0.73
Change:$0.00 (0.29%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$0.73
Buy:$0.73
Change:$0.00 (0.29%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Key people

Esther Rajavelu
Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer
Timothy Keutzer
Chief Operating Officer
Kamal Hamed
Chief Medical Officer
Frank E. Thomas
Independent Chairman of the Board
Patrick Volkert Jo Vink
Lead Independent Director
Satyavrat Shukla
Director
Ankit Mahadevia
Non-Executive Director
Milind S. Deshpande
Independent Director
Click to see more

Key facts

  • EPIC
    SPRO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US84833T1034
  • Market cap
    $40.65m
  • Employees
    32
  • Shares in issue
    55.90m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.